G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Intangible Assets
â‚ą148.5m
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Intangible Assets
â‚ą37B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Intangible Assets
â‚ą18.6B
CAGR 3-Years
2%
CAGR 5-Years
-2%
CAGR 10-Years
31%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Intangible Assets
â‚ą94.5B
CAGR 3-Years
17%
CAGR 5-Years
9%
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Intangible Assets
â‚ą43.3B
CAGR 3-Years
5%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Intangible Assets
â‚ą16.6B
CAGR 3-Years
346%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Intangible Assets?
Intangible Assets
148.5m INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Intangible Assets amounts to 148.5m INR.

What is Glenmark Life Sciences Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
18%

Over the last year, the Intangible Assets growth was -17%. The average annual Intangible Assets growth rates for Glenmark Life Sciences Ltd have been 23% over the past three years , 18% over the past five years .

Back to Top